Key points for investors:
- Strategic M&A: Cencora completed acquisition of a majority stake in OneOncology (ownership increased to ~92%), adding a pharmaceutical-centric MSO to its platform alongside Retina Consultants of America (RCA). Management expects MSO capabilities (clinical research, revenue cycle, data/analytics) to drive medium- and long-term value.
- Raised FY26 outlook: Company raised consolidated adjusted operating income growth guidance to 11.5%–13.5% (previously 8%–10%) and US healthcare solutions operating income guidance to 14%–16%. Consolidated revenue growth guidance raised to 7%–9%. Adjusted diluted EPS guidance reaffirmed at $17.45–$17.75.
- Solid Q1 performance: Adjusted diluted EPS $4.08 (up 9%), consolidated revenue $85.9B (up 5.5%), consolidated gross profit up 18% and consolidated operating income up 12%, driven by US healthcare solutions and RCA contribution.
- Segment details: US Healthcare Solutions strong (revenue $76.2B, operating income +21% including RCA); International revenue up ~10% as reported (6% constant currency) but operating income down due to timing of manufacturer price adjustments in a developing market; Global Specialty Logistics showing improving volumes.
- Cash / cashflow / capital allocation: Cash $1.8B; Q1 negative adjusted free cash flow of $2.4B (seasonal working capital), full-year adj. FCF expected around $3B. Share repurchases paused to prioritize deleveraging after OneOncology financing; dividend growth remains a priority.
- Financing and below‑the‑line items: Interest expense guidance raised to $480M–$500M (reflecting borrowings for OneOncology); management expects ~ $30M of Other income tied to a OneOncology joint venture (UUG) and a related noncontrolling loss add-back that will largely offset prior noncontrolling income lines.
- Near-term headwinds and cadence: Continued headwind from an oncology customer lost to acquisition in 2025 will impact Q2 and Q3 but not Q4; Q2 interest expense expected to be about double Q1 due to seasonal working capital and new debt. Management expects international timing issues to reverse across the year.
- Risks / considerations: Integration execution for OneOncology and RCA, timing of manufacturer price adjustments in international markets, seasonal working capital effects on FCF, and paused share buybacks affecting EPS dynamics in the near term.
Sign In
Buy COR
